CSB-321
Phase 1Small molecule
CSB-321 is one of 46 small molecule programs targeting Immunotherapy. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
84 competitors in Immunotherapy
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Keytruda
Merck & Co.Phase 3
Tecentriq
RochePhase 3
Taxol
TevaPhase 3
Venclexta
AbbViePhase 3
Gazyva
RochePhase 3
Calquence
AstraZenecaPhase 3
Paraplatin
AAvyxa
Phase 3
Yervoy
Bristol-Myers SquibbPhase 2
Imfinzi
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CSB-321. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCytosite Biopharma Inc.